A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Ranpirnase (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Tamir Biotechnology
- 25 Aug 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 18 Jan 2011 Planned end date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 23 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).